Leticia A.
- Country
- France
- Department
- medical oncology
Research Overview
Data & Insights
Has run more than one trial at 0 of 23 partner sites.
Specializations
Breast Cancer and Biomarker-Driven Treatment De-escalation
Letitia Aptecar is involved in clinical research in HER2-positive metastatic breast cancer, with a focus on treatment strategies for disease that remains controlled after prolonged anti-HER2 targeted therapy. This area reflects interest in using molecular markers to guide decisions in advanced breast cancer care.
- HER2-positive metastatic breast cancer
- Circulating tumor DNA
- Therapeutic de-escalation
The therapeutic emphasis lies in refining long-term management for patients with controlled metastatic disease.
Thoracic Oncology and Non-Small Cell Lung Cancer
Her research activity includes non-small cell lung cancer across both resected early-stage disease and oligometastatic settings, with attention to molecular risk assessment and local treatment options. This work spans personalized postoperative care and the integration of ablative approaches in metastatic thoracic disease.
- Resected stage I or IIA non-squamous NSCLC
- Oligometastatic NSCLC
- Molecular prognostic profiling
Her clinical interest in this field is centered on tailoring treatment intensity and combining systemic therapy with local control strategies.
Kidney Cancer and Advanced Renal Cell Carcinoma
Letitia Aptecar is active in research on kidney cancer, particularly metastatic renal cell carcinoma and treatment selection informed by molecular subgrouping. Her involvement covers modern immunotherapy and targeted therapy options used in first-line management of advanced renal malignancy.
- Metastatic kidney cancer
- Renal cell carcinoma molecular subgroups
- Immunotherapy and tyrosine kinase inhibitor strategies
This domain highlights her interest in treatment personalization for advanced renal tumors.
Urologic Oncology and Urinary Bladder Neoplasms
Her clinical research landscape also includes urinary bladder neoplasms and broader urothelial carcinoma care, with attention to advanced or metastatic disease. This area is linked to investigational treatment combinations aimed at improving outcomes in urinary tract cancers.
- Urinary bladder neoplasms
- Advanced urothelial carcinoma
- Combination systemic therapy
The therapeutic focus in this field is on expanding options for difficult-to-treat bladder cancer.
Rare Tumors and Hematologic Conditions
Her research interests extend to poor-prognosis non-seminomatous germ-cell tumors and essential thrombocythaemia, reflecting involvement in both rare solid tumors and selected myeloproliferative disorders. These areas involve distinct therapeutic challenges and specialized clinical management.
- Non-seminomatous germ-cell tumors
- Essential thrombocythaemia
- Rare cancer and blood disorder management
Her medical interest in these domains is directed toward improving care for uncommon and clinically complex diseases.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.